Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aron Schlau

Internal Medicine Palm Harbor, FL Medical Doctor

NPI 1902868904 CMS profile 132174

3820 Tampa Rd, Palm Harbor, FL 34684

Open in the dashboard

General payments

$2,199

5 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$424,326 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Aron Schlau of Palm Harbor, FL is reported in the CMS Open Payments database as having received $2,199 across 5 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $424,326 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 80th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $52 2
2024 General $30 1
2021 General $2,100 1
2019 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aron Schlau
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Aron Schlau were reported at $52. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Aron Schlau Internal Medicine median Middle half National median
2019 $17 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $2,100 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $30 $154 $47–$537 $164
2025 $52 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Eli Lilly and Company $2,100 1 payment
  2. Medtronic, Inc. $30 1 payment
  3. Lilly USA, LLC $26 1 payment
  4. Merck Sharp & Dohme Corporation $26 1 payment
  5. Novo Nordisk Inc $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,100 1 payment
  2. Food and Beverage $99 4 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $30 1 payment
  2. JARDIANCE $26 1 payment
  3. CAPVAXIVE $26 1 payment
  4. Ozempic $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

1,339

Median for Internal Medicine: 777

Drug cost

$52,481

Median for Internal Medicine: $73,373

Branded share of claims

8.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Januvia Sitagliptin Phosphate Brand 34 $26,182
Eliquis Apixaban Brand 16 $11,887
Symbicort Budesonide/Formoterol Fumarate Brand 15 $5,523
Gabapentin Generic 38 $909
Atorvastatin Calcium Generic 129 $794
Levothyroxine Sodium Generic 71 $616
Rosuvastatin Calcium Generic 79 $525
Metoprolol Succinate Generic 43 $515
Duloxetine Hcl Generic 20 $503
Pantoprazole Sodium Generic 45 $369

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$24,570

Of which drugs: $14

Medicare patients

115

Average age 76

Services billed

513

51 women, 64 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 38%
Chronic kidney disease 34%
Depression 24%
Diabetes 23%
COPD 21%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

5 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record